About 180 Life Sciences Corp. - Common Stock (ATNF)
180 Life Sciences Corp is a biotechnology company focused on developing innovative therapeutic solutions across a range of medical conditions, with an emphasis on chronic inflammatory diseases and pain management. The company leverages advanced scientific research to create and commercialize novel drug candidates, utilizing its expertise in cannabinoid therapy and other emerging treatment modalities. By addressing unmet medical needs, 180 Life Sciences aims to enhance patient outcomes and improve the quality of life for individuals suffering from debilitating conditions. Read More
180 Life Sciences Corp. (NASDAQ:ATNF) shares slid 1.45% in after-hours trading on Thursday, coinciding with the decline of the company's primary reserve asset, Ethereum (CRYPTO: ETH).
Intrigued by the market activity in the middle of the day on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Shares of 180 Life Sciences Corp. (NASDAQ:ATNF) climbed Wednesday, extending the previous day's rally, after the company revealed it had accumulated more than $349 million in Ethereum (CRYPTO: ETH) as part of its
Shares of Sapiens International Corporation NV (NASDAQ:SPNS) rose sharply in pre-market trading after it announced on Wednesday that it will be acquired by global private equity firm Advent in an all-cash transaction
180 Life Sciences Corp. (NASDAQ:ATNF) is trending on Wednesday after gaining approximately 228.45% for the day. Check out the current price of ATNF stock here.
Low-priced momentum plays are heating up the tape as earnings beats, insider buys, and strategic deals fuel speculation ahead of key catalysts. From crypto-backed balance sheets to mass retail expansion and sustainable technology breakthroughs, these sub-$5 companies are lining up for potential breakout runs. Traders scanning for under-the-radar opportunities may find this week’s lineup too hot to ignore.
